Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belinostat + carboplatin + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Assertio
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Belinostat + carboplatin + paclitaxel is a combination chemotherapy regimen investigated primarily for the treatment of recurrent or platinum-resistant epithelial ovarian cancer and other solid tumors. Belinostat is a histone deacetylase (HDAC) inhibitor that modulates gene expression by inhibiting HDAC enzymes, leading to cell cycle arrest and apoptosis in cancer cells. Carboplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and subsequent apoptosis. Paclitaxel stabilizes microtubules and inhibits their disassembly, disrupting mitosis and promoting cell death. The combination has been evaluated in phase I/II clinical trials; it was generally well tolerated with manageable toxicity profiles but did not show significant improvement in progression-free survival compared to standard regimens. The regimen has demonstrated some clinical benefit in heavily pretreated patients with ovarian cancer[1][2][3].
- Brand names
- Beleodaq + Paraplatin + Taxol
- Other names
- BelCaP
02
Targets
DNAHDAC (HDAC family)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on belinostat + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belinostat + carboplatin + paclitaxel.